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Abstract: Inflammation has been suggested to play a pathophysiological role in anorexia nervosa
(AN). In this exploratory cross-sectional study, we measured serum concentrations of 40 inflammatory
markers (including cytokines, chemokines, and adhesion molecules) and brain-derived neurotrophic
factor (BDNF) in people with AN (n = 27) and healthy controls (HCs) (n = 13). Many of these
inflammatory markers had not been previously quantified in people with AN. Eating disorder
(ED) and general psychopathology symptoms were assessed. Body mass index (BMI) and body
composition data were obtained. Interleukin (IL)-6, IL-15, and vascular cell adhesion molecule
(VCAM)-1 concentrations were significantly elevated and concentrations of BDNF, tumor necrosis
factor (TNF)-β, and vascular endothelial growth factor (VEGF)-A were significantly lower in AN
participants compared to HCs. Age, BMI, and percentage body fat mass were identified as potential
confounding variables for several of these inflammatory markers. Of particular interest is that most of
the quantified markers were unchanged in people with AN, despite them being severely underweight
with evident body fat loss, and having clinically significant ED symptoms and severe depression and
anxiety symptoms. Future research should examine the replicability of our findings and consider the
effect of additional potential confounding variables, such as smoking and physical activity, on the
relationship between AN and inflammation.
Keywords: anorexia nervosa; inflammatory markers; inflammation; cytokines; chemokines;
adhesion molecules
1. Introduction
Anorexia nervosa (AN) is a serious psychiatric disorder characterised by low body weight due to
food restriction and weight-control behaviours, such as excessive exercise and self-induced vomiting,
together with an intense fear of weight gain and disturbed body perception [1]. Altered concentrations
of inflammatory markers, in particular cytokines, have been reported in people with AN [2,3].
Cytokines are cell signalling molecules produced by a range of cells (e.g., microglia, astrocytes) in the
brain and the periphery (e.g., by macrophages and T-lymphocytes) and are essential in coordinating
responses to infection [4]. In addition, changes in the circulating concentrations and production of
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cytokines have been associated with a range of disease states, including obesity [5] and diabetes [6],
as well as depression [7], schizophrenia [8], and eating disorders (EDs) [2,3].
Research in AN has primarily focused on pro-inflammatory cytokines, which promote and up-regulate
inflammatory reactions [4]. Recent meta-analyses have concluded that the pro-inflammatory cytokines
tumor necrosis factor (TNF)-α and interleukin (IL)-6, are elevated in people with AN, compared to
healthy individuals (for reviews see: [2,3]). However, few studies have quantified the concentrations
of cytokines in other categories, such as T-helper (TH)-1, TH2, and anti-inflammatory cytokines (e.g.,
IL-10), the latter of which play an immunomodulatory role by reducing inflammation [9]. An example
of one such cytokine yet to be measured in people with AN is TNF-β, which is produced by TH1
cells. TNF-β performs a variety of important roles in immune regulation [10,11], but has also been
implicated in the regulation of the commensal gut microbiota [12–14], which appears to be involved
in the pathology of AN [15–17]. Additionally, a number of cytokines implicated in other disorders,
such as depression and obesity, are yet to be measured in AN. One example is IL-17, a TH17 cytokine
that has been reported to predict treatment response in people with depression [18], and seems to
be involved in the pathophysiology of schizophrenia [19] and the molecular and cellular effects of
antipsychotics [20].
Chemokines are a subcategory of smaller cytokines known to induce chemotaxis, with some
also having a homeostatic function in relation to haematopoiesis, immune surveillance, and adaptive
immune system responses [21,22]. The chemokines RANTES, monocyte chemoattractant protein
(MCP)-1, and fractalkine have been measured in two studies in people with AN [23,24]. Similarly,
adhesion molecules, which mediate the binding of cells in the immune system [25], have been measured
in one study in a sample of people with AN [26]. Circulating concentrations of vascular cell adhesion
molecule (VCAM)-1 have been reported to be elevated in people with AN compared to healthy
participants, but intercellular adhesion molecule (ICAM)-1 did not differ between the groups.
Cytokines and chemokines impact several biological domains implicated in the pathophysiology
of AN, including the modulation of neurotransmitter systems, neuroendocrine functioning, and neural
plasticity [27–31]. For example, in the depression literature, it has been hypothesised that elevated
pro-inflammatory cytokine levels may lead to symptoms of depression, partly via their disruption of
growth factor production, e.g., brain-derived neurotropic factor (BDNF) [32] and vascular endothelial
growth factor (VEGF)-A [33], which has a subsequent effect on adult neurogenesis [28,34]. Disruption
to these biological processes can then lead to alterations in mental state, including affect, learning and
memory, and behaviour (e.g., depressive-like behaviours) [28,35].
A number of factors, including body mass index (BMI), age, medication, and smoking status,
have been reported to influence cytokine concentrations [36]. These may be potential confounding
factors in studies of the role of cytokines in AN, particularly given the low weight seen in AN,
the tendency for research in EDs to focus on adolescents and young adults [2], and research indicating
that people with EDs report higher rates of smoking than healthy controls [37]. Previous studies
have not assessed the potential impact of depression symptoms on cytokine concentrations in AN.
A pro-inflammatory profile has been identified in people with depression [38] and the comorbidity
between AN and unipolar depression is of significant clinical relevance, as approximately 40% of
people receiving treatment for AN also suffer from depression [39]. Therefore, it is unclear as to
whether the alterations observed in cytokine concentrations are due to the AN or symptoms of
comorbid disorders, such as depression.
Few studies have considered a broad range of cytokines and other markers involved in
inflammatory processes and their potential role in the biological profile of AN. Therefore, in this
exploratory cross-sectional study, we measured a variety of inflammatory markers in a sample of AN
participants and healthy controls (HCs) to determine whether these markers are altered in AN. Several
of these inflammatory markers have not been previously quantified in people with AN. A secondary
objective was to test for the effects of potential confounders on concentrations of the inflammatory
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markers, including age and BMI, and explore the effect of current symptom severity on markers of
inflammation in people with AN.
2. Materials and Methods
2.1. Participants and Study Design
Between 2010 and 2013, 55 participants with AN (outpatients n = 27; day-patients n = 10; inpatients
n = 18) and 30 HCs were recruited as part of the “Relationship between Overactivity, Stress and Anxiety
in Anorexia Nervosa” (ROSANA) study [40,41]. Female adults with a primary diagnosis of AN
(restricting or binge-eating/purging type) and a BMI < 17.5 kg/m2 were recruited within the first four
weeks of treatment for AN via Specialist Eating Disorder Services in and around London. HCs (n = 30)
were recruited via an e-mail circular to students and staff at King’s College London. Exclusion criteria
for HCs were a history of or current mental health disorder, including EDs, and the presence of physical
illness, which were assessed in the initial research session using a specially designed record form
and the research version of the Structured Clinical Interview for Diagnostic and Statistical Manual of
Mental Disorders (DSM)-IV Axis I Disorders [42], described below. All participants provided informed
consent before study participation. The study was conducted in accordance with the Declaration
of Helsinki and the study received ethical approval from the South East London Research Ethics
Committee (REC ref: 09/H0807/4).
2.2. Measures
2.2.1. Demographic Characteristics and Screening
A specially designed record form was used to collect demographic data and additional information
relating to the inclusion and exclusion criteria described above, e.g., the presence of medical conditions.
To determine smoking status, participants were asked if they smoked and if so, to report the number
of cigarettes smoked per day. For AN participants, illness duration (in this case, time since diagnosis)
was also recorded. All participants completed the research version of the Structured Clinical Interview
for DSM-IV Axis I Disorders [42], a validated structured interview, to confirm diagnosis in the AN
participants and identify a history of and/or current mental health problems in the HCs.
2.2.2. Anthropometry
Height and body weight were measured, and from these measurements, BMI (kg/m2) was
calculated. Body composition was also measured using a portable and non-invasive Inbody S10
machine (Inbody Co., Ltd., Seoul, Korea) which uses the Bioelectrical Impedance Analysis (BIA)
measurement method. Following the input of height and weight details, this machine provides data
on muscle and fat, bone mineral content, intracellular and extracellular water, protein, and minerals.
The calculations used to do this are based on the assumption that the body is a cylindrical-shaped
conductor. Resistance is low in lean tissue (as it contains the majority of intracellular and extracellular
fluid and is thus a good conductor of electrical current), and fat mass is high in resistance as it is does
not contain any water (and thus does not conduct electrical current). Based on the assumption that
impedance (resistance) is proportional to total body water, predictive equations then determine total
body water, total body fat, and lean tissue mass. Given that adipose tissue has been implicated in the
genesis of cytokines and produces certain pro-inflammatory cytokines (e.g., IL-6), we focused on the
association between inflammatory markers and body fat percentage and did not include other body
composition parameters in our analyses.
2.2.3. Eating Disorder Behaviours and General Psychopathology
ED symptoms were assessed using the Eating Disorder Examination-Questionnaire (EDE-Q) [43].
This questionnaire has 36-items assessing ED symptoms and behaviours over the previous 28 days.
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A global score can be calculated, and items can also be categorised and scored into the following four
subscales: restraint, eating concern, weight concern, and shape concern. Related psychopathology
was assessed using the Depression Anxiety Stress Scale 21-Version (DASS-21) [44]. This is a 21-item
questionnaire measuring symptoms of general psychopathology over the previous seven days. As well
as a total score, a score for the three subscales—depression, anxiety, and stress—can be calculated.
Additional measures related to physical activity were also collected and findings are reported
elsewhere [40,41].
2.2.4. Inflammatory Markers
Blood samples were collected, and serum was stored at −80 ◦C prior to use. Serum was thawed at
room temperature and the concentrations of 42 inflammatory markers were quantified simultaneously
using multiplex ELISA-based technology provided by the Meso Scale Discovery V-PLEX Human
Biomarker 40-Plex Kit and a customised human duplex kit assaying BDNF and interferon (IFN)-α,
following the manufacturer’s instructions (Meso Scale Diagnostics, LLC., Rockville, MD, USA). Cases
and controls were randomised across batches, and plates were scanned on the Mesoscale Scale
Discovery MESO Quickplex SQ 120 reader at the MRC SGDP Centre, Institute of Psychiatry, Psychology
& Neuroscience, King’s College London. The inflammatory markers measured in the 40-plex array
were: basic fibroblast growth factor (bFGF), C-reactive protein (CRP), Eotaxin, Eotaxin-3, Fms-like
tyrosine kinase (Flt)-1, granulocyte-macrophage colony-stimulating factor (GM-CSF), ICAM-1, IFN-γ,
IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A,
interferon γ-induced protein (IP)-10, MCP-1, MCP-4, macrophage inflammatory protein (MIP)-1α,
MIP-1β, placental growth factor (PlGF), serum amyloid A (SAA), thymus and activation-regulated
chemokine (TARC), tyrosine kinase (Tie)-2, TNF-α, TNF-β, VCAM-1, VEGF-A, VEGF-C, and VEGF-D.
The assay for macrophage-derived chemokine (MDC) was not included in the current panel due to
quality control issues.
2.3. Statistical Analysis
Thirty-two AN and 14 HC participants had available blood samples. One HC participant
was excluded from the analyses due to having a BMI below 18.5 kg/m2, i.e., in the underweight
range. Five AN participants were excluded from analyses due to reported autoimmune and/or
inflammatory diseases. Therefore, the current cross-sectional analyses are based on a sample consisting
of 27 participants with a diagnosis of AN and 13 HCs.
Standard curves were used to determine absolute quantities (pg/mL) of each inflammatory
marker. All statistical analyses were performed in Stata 15 [45].
2.3.1. Cross-Sectional Comparisons
For demographics and clinical characteristics, group comparisons were assessed using t-tests or
Mann-Whitney U-tests depending on the distribution of the data. Log-transformation of inflammatory
marker values was conducted due to the presence of outliers and non-normal distributions; however,
data remained non-normal for most of the measured molecules. Therefore, Mann-Whitney U-tests
were employed to compare concentrations of inflammatory markers between the AN and HC groups.
IFN-α was only detected in three samples (two HC and one AN); the results are therefore not presented.
2.3.2. Exploratory Regression Analyses
Absolute quantities of the inflammatory markers (pg/mL) were log-transformed to allow for
regression analyses. To identify marker-specific confounders, linear regressions were performed
for each log-transformed inflammatory marker (as the dependent variable) with each potential
confounding variable (age, BMI, percentage fat mass) separately in the whole sample. To test the
effect of illness severity on inflammatory marker concentrations, we performed linear regressions in
the AN participants, with the log-transformed inflammatory marker as the dependent variable and
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illness duration or ED symptoms, as measured by the EDE-Q, as the independent variable. To test
the effect of general psychopathology on inflammatory marker concentrations, linear regressions
in the AN participants, with the log-transformed inflammatory marker as the dependent variable
and the total DASS-21 score as the independent variable, were conducted. For both sets of analyses,
studentized residuals greater than ±3 standard deviations were deemed to be outliers and were
removed, and assumptions were tested and met.
The level of significance was set at p < 0.05, and as this was an exploratory study, levels of
significance were not adjusted for multiple testing.
3. Results
Demographic, anthropometric, and clinical characteristics of the AN participants and HCs are
presented in Table 1. All participants were female. Mean age did not significantly differ between the
AN and HC groups (U = 144, z = −1.36, p = 0.1735). Seven participants with AN reported being a
current smoker, with an average of 9.14± 5.90 cigarettes smoked per day. As expected, AN participants
had lower BMI (t (38) = 7.88, p < 0.001) and percentage body fat (U = −22, z = 3.63, p = 0.0003) scores,
and higher EDE-Q scores (global score: U = 85.5, z = −4.87, p < 0.001) than HCs. The EDE-Q global
score for the AN participants was greater than the commonly used clinical cut-off score of 4 e.g., [46,47].
AN participants also reported greater depression, anxiety, and stress than HCs on the DASS-21 (total
score: U = 92.5, z = −4.67, p <0.001). Proposed cut-off scores [44] suggest that the level of severity that
AN participants reported was severe for depression, anxiety, and stress.
Table 1. Demographic, anthropometric, and clinical characteristics for AN participants and HCs.
Demographic, Anthropometric,
and Clinical Characteristics
Healthy Controls
(n = 13)
Anorexia Nervosa
(n = 27) p Value
Demographics
Age (years) (mean ± SD) 25.54 ± 4.52 31.48 ± 11.40 0.1735
Current smoker (n) 0 a 7
Anthropometrics
BMI (kg/m2) (mean ± SD) 20.88 ± 1.68 15.33 ± 2.25 <0.0010
Body fat (%) (mean ± SD) 17.08 ± 6.05 b 7.76 ± 6.07 0.0003
Clinical characteristics
Duration of diagnosis, years (mean ± SD) 11.64 ± 11.54 c
AN-R/AN-BP (n) 12/15
Current outpatient/inpatient (n) 16/11
EDE-Q Global (mean ± SD) 0.66 ± 0.70 4.20 ± 1.27 <0.0010
EDE-Q Restraint (mean ± SD) 0.62 ± 0.88 4.04 ± 1.77 <0.0010
EDE-Q Eating Concern (mean ± SD) 0.26 ± 0.48 3.82 ± 1.28 <0.0010
EDE-Q Weight Concern (mean ± SD) 0.74 ± 0.83 4.13 ± 1.59 <0.0010
EDE-Q Shape Concern (mean ± SD) 1.02 ± 0.85 4.82 ± 1.24 <0.0010
DASS-21 Total (mean ± SD) 13.85 ± 13.89 72.30 ± 33.32 <0.0010
DASS-21 Depression (mean ± SD) 3.54 ± 5.43 24.59 ± 13.73 <0.0010
DASS-21 Anxiety (mean ± SD) 3.08 ± 4.94 19.48 ± 11.84 0.0001
DASS-21 Stress (mean ± SD) 7.23 ± 5.20 28.22 ± 10.69 <0.0010
a n = 6 missing; b n = 1 missing; c n = 3 missing. Abbreviations: HCs—healthy controls; AN—anorexia nervosa;
SD—standard deviation; BMI—body mass index; AN-R—anorexia nervosa restricting type; AN-BP—anorexia
nervosa binge-eating/purging type; EDE-Q—Eating Disorder Examination—Questionnaire; DASS-21—Depression
Anxiety and Stress Scales-21 Version.
3.1. Inflammatory Markers
3.1.1. Cross-Sectional Comparison
The median concentrations (pg/mL) of the quantified inflammatory markers, along with the
interquartile range, and minimum and maximum values, for HCs and AN participants are shown in
Table 2. Median serum levels of TNF-β (U = 76, z = 2.87, p = 0.004) and VEGF-A (U = 102, z = 2.12,
p = 0.030) were lower in AN participants than in HCs. Median concentrations of IL-6 (U = 92, z =−2.41,
p = 0.016), IL-15 (U = 85, z = −2.61, p = 0.009), and VCAM-1 (U = 106, z = −2.01, p = 0.032) were found
to be higher in AN participants compared to HCs. No other inflammatory parameters were found to
differ between groups.
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Table 2. Median serum concentrations (pg/mL), with interquartile range (IQR), minimum and maximum values, of inflammatory markers for HCs and AN participants.
Inflammatory
Marker
Healthy Controls Anorexia Nervosa p Value
N Median IQR Min Max N Median IQR Min Max
a. Concentrations significantly lower in AN compared to HCs
BDNF 13 17,375.24 7862.72 10,526.40 21,884.09 27 12,799.75 5947.87 7792.55 23,003.72 0.0315
TNF-β 13 0.86 0.32 0.43 53.22 27 0.60 0.19 0.16 1.22 0.0041
VEGF-A 13 471.96 220.76 205.98 749.41 27 288.82 155.41 133.70 973.73 0.0338
b. Concentrations significantly higher in AN compared to HCs
IL-6 13 0.38 0.29 0.10 1.11 27 0.49 0.90 0.20 3.35 0.0159
IL-15 13 2.54 0.39 1.91 3.18 27 2.90 0.81 1.57 5.24 0.0090
VCAM-1 13 612,378.30 92,337.87 402,297.20 739,682.80 27 709,059.60 220,832.10 434,057.50 1,069,997.00 0.0448
c. Concentrations not significantly different between groups
bFGF 13 11.01 10.73 2.17 21.13 27 12.13 13.39 1.15 65.25 0.3334
CRP 13 332,422.10 1,497,240.00 38,821.00 4,878,443.00 27 342,975.80 5,408,764.00 39,716.48 37,500,000.00 0.9424
Eotaxin 13 208.55 61.81 136.51 285.80 27 175.47 123.38 101.36 511.08 0.8511
Eotaxin-3 13 20.55 6.48 9.95 112.91 27 15.15 14.22 5.14 60.87 0.1058
Flt-1 13 61.83 11.64 27.93 86.21 27 68.69 28.37 11.99 117.06 0.1224
GM-CSF 13 0.15 0.21 0.02 0.88 22 0.19 0.17 0.01 0.35 0.8779
ICAM-1 13 658,988.00 183,427.10 517,283.10 861,717.20 27 701,224.80 244,044.70 415,274.60 977,044.00 0.1224
IFN-γ 13 3.94 1.64 2.11 6.84 27 4.64 5.72 2.11 64.28 0.1448
IL-1α 13 1.13 1.32 0.41 3.51 27 1.01 0.64 0.44 6.00 0.4105
IL-1β 9 0.20 0.33 0.04 1.86 21 0.19 0.19 0.01 4.07 0.7343
IL-2 6 0.12 0.24 0.03 0.43 13 0.15 0.16 0.01 0.85 0.9301
IL-4 13 0.08 0.07 0.01 0.20 25 0.05 0.05 0.00 5.24 0.1481
IL-5 12 1.09 0.87 0.43 3.45 24 1.29 1.01 0.07 4.39 0.7626
IL-7 13 13.66 6.11 8.76 20.13 27 12.58 6.80 5.82 26.20 0.8966
IL-8 13 33.51 62.10 8.44 503.23 27 23.09 92.94 5.80 388.41 0.4271
IL-10 13 0.18 0.10 0.06 0.41 27 0.28 0.26 0.04 4.40 0.3120
IL-12/IL-23p40 13 117.69 49.83 72.15 250.50 27 92.00 50.59 38.72 220.89 0.0806
IL-12p70 11 0.18 0.09 0.01 0.53 25 0.19 0.25 0.01 1.06 0.7572
IL-13 9 2.95 3.25 1.53 10.34 17 2.44 3.13 0.76 6.35 0.2692
IL-16 13 160.52 58.89 99.73 291.95 27 183.59 194.22 127.93 463.24 0.1702
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Table 2. Cont.
Inflammatory
Marker
Healthy Controls Anorexia Nervosa p Value
c. Concentrations not significantly different between groups
IL-17A 13 1.78 1.94 0.36 3.85 27 1.91 1.51 0.63 43.83 0.9539
IP-10 13 110.93 57.70 75.89 175.65 27 115.99 108.88 72.71 596.43 0.3191
MCP-1 13 208.55 126.78 140.94 406.88 27 191.53 77.31 121.51 345.28 0.3480
MCP-4 13 142.79 80.25 54.04 212.93 27 120.65 83.26 53.61 290.55 0.6133
MIP-1α 13 25.01 7.73 16.36 56.15 27 23.02 15.10 15.68 66.68 0.8624
MIP-1β 13 102.15 62.83 34.70 280.41 27 81.06 44.32 41.10 271.72 0.3334
PlGF 13 3.38 1.57 1.91 6.06 27 3.85 1.81 1.71 6.21 0.6754
SAA 13 2,683,488.00 1,218,569.00 318,141.50 13,200,000.00 27 2,681,116.00 9,488,702.00 525,220.00 164,000,000.00 0.8061
TARC 13 365.16 319.52 168.47 690.47 27 370.33 378.45 68.69 7680.34 0.7617
Tie-2 13 5847.41 2784.74 4065.41 8455.58 27 6212.88 3028.74 2440.01 10,077.48 0.7617
TNF-α 13 1.59 0.50 0.91 2.70 27 1.64 1.08 0.61 2.95 0.8966
VEGF-C 13 574.92 119.71 242.97 739.49 27 449.26 243.10 277.52 852.72 0.2919
VEGF-D 13 790.06 358.08 383.69 1126.91 27 757.22 413.20 458.68 1906.49 0.8061
Abbreviations: IQR—interquartile range; min—minimum; max—maximum; AN—anorexia nervosa; HC—healthy controls; BDNF—brain-derived neurotrophic factor; TNF—tumor
necrosis factor; VEGF—vascular endothelial growth factor; IL—interleukin; VCAM-1—vascular cell adhesion molecule-1; bFGF—basic fibroblast growth factor; CRP—C-reactive protein;
Flt-1—Fms-like tyrosine kinase-1; GM-CSF—granulocyte-macrophage colony-stimulating factor; ICAM-1—intercellular adhesion molecule-1, IFN-γ—interferon- γ; IP-10—interferon
γ-induced protein-10; MCP—monocyte chemoattractant protein; MIP—macrophage inflammatory protein; PlGF—placental growth factor; SAA—serum amyloid A; TARC—thymus and
activation-regulated chemokine; Tie-2—tyrosine kinase-2.
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3.1.2. Identification of Marker-Specific Confounding Variables
The full findings of the regressions assessing age, BMI, and percentage fat mass as potential
confounders of the serum concentrations of inflammatory markers across all participants are shown in
Table S1. Age significantly influenced the serum concentrations of Eotaxin-3 (F(1, 37) = 5.68, p = 0.0224),
IFN-γ (F(1, 33) = 7.91, p = 0.0082), MCP-1 (F(1, 38) = 8.87, p = 0.0050), MIP1-α (F(1, 38) = 4.48, p = 0.0408),
SAA (F(1, 38) = 6.99, p = 0.0119), and TNF-α (F(1, 38) = 5.07, p = 0.0302). BMI significantly predicted
concentrations of IL-4 (F(1, 34) = 4.73, p = 0.0367), IL-6 (F(1, 38) = 9.48, p = 0.0039), IL-10 (F(1, 37) = 6.67,
p = 0.0139), IL-12/IL-23p40 (F(1, 38) = 10.97, p = 0.0020), IL-15 (F(1, 38) = 9.54, p = 0.0037), TNF-β
(F(1, 35) = 7.45, p = 0.0098), and VEGF-C (F(1, 37) = 6.17, p = 0.0177). Percentage fat mass significantly
influenced IL-6 (F(1, 38) = 8.83, p = 0.0052), IL-12/IL-23p40 (F(1, 37) = 10.05, p = 0.0031), TNF-β
(F(1, 35) = 4.93, p = 0.0331), and VEGF-C (F(1, 38) = 5.00, p = 0.0315). Age, BMI, and percentage fat mass
were not found to be associated with concentrations of any of the remaining inflammatory markers.
3.1.3. Effect of Illness Severity
Full results from the regressions determining the effect of illness severity, in relation to illness
duration, ED symptoms, and general psychopathology, on serum concentrations of the inflammatory
markers in AN participants only are shown in Table S2. Illness duration of AN participants significantly
predicted serum concentrations of IL-4 (F(1, 18) = 15.82, p = 0.0009), IL-12/IL-23p40 (F(1, 21) = 6.70,
p = 0.0172), MCP-1 (F(1, 21) = 6.40, p = 0.0194), and VEGF-A (F(1, 22) = 5.55, p = 0.0278). Severity of ED
symptoms in AN participants, as measured by the EDE-Q, predicted serum concentrations of IP-10
(F(1, 23) = 12.60, p = 0.0017) and PlGF (F(1, 25) = 4.44, p = 0.0454). Level of general psychopathology
(symptoms of depression, anxiety, and stress, as measured by the DASS-21) significantly predicted
Eotaxin (F(1, 25) = 4.64, p = 0.0410), IL-7 (F(1, 25) = 4.60, p = 0.0419), IL-8 (F(1, 25) = 10.08, p = 0.0040),
IP-10 (F(1, 25) = 6.06, p = 0.0211), MCP-1 (F(1, 25) = 5.43, p = 0.0282), and TARC (F(1, 22) = 9.18,
p = 0.0062) concentrations. No other inflammatory markers were significantly associated with illness
duration or severity of ED and general psychopathology symptoms.
3.2. Brain-Derived Neurotrophic Factor
Median serum levels of BDNF were reduced in AN participants compared to HCs (U = 101,
z = 2.15, p = 0.0320). Concentrations of BDNF were significantly influenced by BMI (F(1, 38) = 13.86,
p = 0.0007) and percentage body fat mass (F(1, 38) = 7.08, p = 0.0114), but not by age, as shown in
Table S1. Illness duration, ED symptom severity, and general psychopathology symptoms were not
associated with serum concentrations of BDNF (see Table S2).
4. Discussion
4.1. Summary of Findings
We measured a range of markers involved in inflammatory processes, including cytokines,
chemokines, acute-phase reactants, and cell adhesion molecules, in people with AN and HCs. Median
concentrations of BDNF, IL-6, IL-15, TNF-β, VCAM-1, and VEGF-A were found to differ between
AN and HCs, with IL-6, IL-15, and VCAM-1 being elevated in AN, and BDNF, TNF-β, and VEGF-A
being reduced, compared to HCs. No other inflammatory markers differed between AN participants
and HCs. Our exploratory analyses also identified potential confounding variables of these markers,
including age, BMI, and percentage fat mass, which should be considered in future studies. Illness
severity, both with respect to ED and general psychopathology symptoms, predicted concentrations of
certain inflammatory markers that were not found to differ between AN participants and HCs. Of the
markers with significant cross-sectional differences, illness duration predicted serum concentrations
of VEGF-A.
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4.1.1. Inflammatory Markers
Given that the AN patients in this sample are seriously unwell, as evidenced by their low BMI,
the loss of fat mass, and the presence of clinically significant ED and severe depression and anxiety
symptoms, the finding that most inflammatory markers (n = 33) were unchanged may seem somewhat
surprising. However, it has been proposed that the functioning of the immune system is relatively
preserved in AN, despite malnutrition [48]. For example, extensive evidence suggests that patients
with AN tend to be free from infectious diseases, and rarely have colds and/or flu (at least until
very advanced stages of the disease) [48,49], which is in contrast to the heightened risk of infection
observed in those with typical malnutrition. A recent in vitro study of immune parameters in people
with AN reported that despite reductions in some immune cell populations, AN is also associated with
enhanced antioxidant potential and anti-inflammatory status, in comparison to HCs [50]. This may
contribute to the preservation of immune system functioning reported in AN. However, it needs
to be considered that data derived from in vitro methods may not reflect how cells would respond
in vivo. An additional contributing factor could be a relatively sustained/unaffected gut barrier
function in AN [51], in spite of the distinct alterations of the gut microbiome and low gut microbiome
diversity reported in AN patients [15]. A ‘leaky gut’ is associated with low-grade inflammation
(i.e., leaking of bacteria and/or their components from the gut into circulation is thought to elicit an
inflammatory response) [52,53]; therefore, sustained gut permeability will reduce the likelihood of an
inflammatory response.
To the best of our knowledge, this is the first time serum concentrations of IL-15, TNF-β,
and VEGF-A have been measured and were found to be altered in AN patients. Therefore, we have
discussed the potential significance of these findings in more detail.
IL-15, a T cell growth factor, has been suggested to be involved in the modulation of serotonergic
transmission [54,55], which may underlie the depressive symptoms and sleep disturbances that
are often present in people with AN, and fits with existing evidence of serotonergic alterations in
AN [56,57]. Elevations of IL-15 levels have also been reported in patients with schizophrenia [58],
which is interesting in light of the possible genetic overlaps between AN and schizophrenia that have
been identified in genome-wide association study (GWAS) data [59]. IL-15 has also been implicated
in cross-talk between fat and muscle and reported to have an anabolic role, i.e., decreasing fat and
increasing muscle mass [60]. It is unclear, therefore, why it is increased in the anorectic group given
that they show a severe loss of body fat. It may, for example, be raised as a way of trying to maintain
muscle mass in the ill state.
TNF-β (also known as lymphotoxin-α) has several roles in immune regulation [10] and is
involved in the regulation of cell survival, proliferation, differentiation, and apoptosis [11]. A TNF-β
polymorphism (+252G/A) has been proposed to increase the risk of developing schizophrenia [61].
TNF-β also has a role in maintaining lipid homeostasis, which is potentially important in AN. However,
what is perhaps of most interest is that it is involved in regulating intestinal microbiota [12–14],
especially as the gut microbiome has been implicated in the pathophysiology of AN e.g., [15].
VEGF-A induces angiogenesis, vasculogenesis, and endothelial cell growth, and also influences
vascular permeability, similar to VCAM-1 [62]. Altered levels of VEGF-A have also been found in
patients with depression [63] and schizophrenia [64]. Lastly, VEGF-A has been suggested to enhance
adult neurogenesis and hippocampus-dependent learning and memory [33], which may be important
in both responsivity to illness and in relation to therapy.
Taken together, changes in IL-15, TNF-β, and VEGF-A could potentially contribute to the
development of AN symptoms, such as low mood and disturbed sleep, as well as its clinical
consequences, such as impaired learning and memory. Furthermore, they provide a link between
the biological pathophysiology of AN with depression and schizophrenia, which are clinically- and
genetically-related psychiatric disorders. This association may be suggestive of inflammatory markers
being indicators of transdiagnostic symptoms, such as low mood, rather than specific psychiatric
diagnoses. Also, such a biological association between these disorders could have clinical and
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therapeutic relevance. For example, we could consider the question as to whether antipsychotics,
such as olanzapine, which is approved for the treatment of schizophrenia and alters cytokine
production [65], might help patients with AN [31,66]. This may also be of particular interest in
AN as olanzapine has been shown to alter the gut microbiome, which could additionally contribute to
weight gain [67–70].
The findings of increased IL-6 and VCAM-1 serum concentrations in our sample of people with
AN compared to HCs are of less novelty, but indicate the reliability of our findings, as these results
have also been reported previously.
As described, there are already a number of studies that have consistently identified an association
between AN and the pro-inflammatory cytokine IL-6 [2]. IL-6 is an inducer of the acute-phase response,
which has been shown to have suppressive effects on food intake [71] and inhibit adipogenesis [72].
Our results replicated the findings of increased concentrations of IL-6 in people with AN, as compared
to HCs.
Víctor et al. [26] previously reported increased VCAM-1 serum levels in patients with AN.
VCAM-1 is a cell adhesion molecule with a key role in leukocyte recruitment from blood into tissue
and is thus important for cellular immune response [73]. Because of its wide distribution in human
tissues and organs, VCAM-1 has been implicated in the development of a variety of pathophysiological
states in the brain and in the body periphery, including autoimmune diseases, cardiovascular disease,
and infections [74].
It is unclear why these particular inflammatory markers are altered in people with AN compared
to HCs. However, there are a number of potential factors which may contribute to these alterations,
including stress and neuroendocrine functioning, genetics, the gut microbiota, early life stress,
and negative health behaviours (e.g., disturbed sleep, altered diet, smoking) [75].
4.1.2. Brain-Derived Neurotrophic Factor
The reduced serum concentrations of BDNF in AN participants compared to HCs is consistent
with previous findings [76]. BDNF is a neurotrophin implicated in both central and peripheral
nervous system development. It is well-established that BDNF and cytokines cross-regulate each other.
Certain pro-inflammatory cytokines can suppress the expression of BDNF [34] and BDNF-dependent
synaptic plasticity [32]. It is thought that the detrimental effect of pro-inflammatory cytokines on
neuroplasticity may be mediated by BDNF [34]. Taking together the evidence in AN of elevated
pro-inflammatory cytokines [2,3], reduced concentrations of BDNF and VEGF-A [76], and reduced
hippocampal volumes [77,78], a key area for adult neurogenesis, it could be hypothesised that this
mechanism may be at play in AN, as proposed in the depression literature [34,79]. This hypothesis
would be consistent with the high prevalence (approximately 40%) of depression in patients with
AN [39].
4.1.3. Marker-Specific Confounding Variables
Our exploratory regression analyses found that BMI significantly predicted BDNF, IL-4, IL-6,
IL-10, IL-12/IL-23p40, IL-15, TNF-β, and VEGF-C concentrations. BDNF, IL-6, IL-12/IL-23p40, TNF-β,
and VEGF-C were also significantly predicted by percentage fat mass. Previous studies assessing IL-6
in AN have failed to control for BMI in cross-sectional analyses. Therefore, we cannot be certain that
the alterations we identified in concentrations of BDNF, IL-6, IL-15, and TNF-β are attributable to AN,
rather than simply BMI or percentage fat mass. We also identified age as a significant confounder
of Eotaxin-3, IFN-γ, MCP-1, MIP1-α, SAA, and TNF-α. Therefore, studies in larger samples with
adequate power should ensure that BMI, and other confounding variables, such as age and percentage
fat mass, are incorporated into analyses as covariates to further explore this relationship. Research is
also needed to consider the effect of additional potential confounding variables on the relationship
between AN and inflammation. Physical activity, for example, may be particularly pertinent in AN
patients, given that excessive exercise is often a key feature of the disorder.
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4.2. Strengths and Limitations
This study is the first to measure several inflammatory markers in patients with AN, including
IL-15 and TNF-β, identifying several alterations in inflammatory markers in AN that warrant future
research in larger samples. We also assessed illness severity, in terms of illness duration; ED
symptoms, including psychological and anthropometric measures; and associated psychopathology
(e.g., depression and anxiety), in our participants. Few previous studies have included such
variables [2], which in the current study have allowed us to explore the relationship between illness
severity and inflammatory markers. In addition, for the HCs, the median values of a number of the
assessed markers are similar to those observed in previous studies, suggesting that our HC group is a
valid comparison group.
Several limitations should be noted. The sample is small, which limits the power in this study and
due to the exploratory nature, we did not correct for multiple testing, thus increasing the likelihood of
receiving a significant result. Additionally, while the AN and HC groups did not differ in mean age,
it must be mentioned that the AN group had a larger age range (18–67 years) than the HCs (20–36 years).
The AN sample included both inpatients and outpatients; differences between these treatment settings
in the opportunity to engage in ED behaviours, such as calorie restriction, self-induced vomiting,
and excessive exercise, may effect cytokine concentrations e.g., [80,81]. As BIA measurements of body
composition are influenced by fluid and electrolyte status (for which there are known imbalances in
AN and these parameters are reported to be particularly affected in early refeeding), the accuracy
of BIA measurements of body composition may be limited, particularly in the AN group [82,83].
For practical reasons, it was not possible to ensure blood samples were drawn at a specific time of
day and as cytokine production and release is reported to occur in a circadian manner, it is possible
that some natural variations may have occurred [84]. As previously described, the inflammatory
markers measured in the current study can be affected by a number of pre-analytical factors [36],
including age, BMI, smoking, and medication. We did not have data on medication for all participants;
however, research has shown that antidepressant and antipsychotic medication can influence cytokine
concentrations and production [20,85]. As these medications are prescribed to AN patients to target
comorbid features of AN, such as depression and/or to induce weight gain [31], it would be important
to identify medication status and incorporate this into analyses as a potential covariate. However,
the limited power in this study precludes more complex analyses, such as incorporating several
confounding variables or considering the effect of nominal confounders, such as smoking status,
on inflammatory markers. Overall, future investigations of inflammatory markers in AN need to ensure
that such confounders are assessed and reported, and if possible, accounted for in statistical analyses.
5. Conclusions
This exploratory study measured a broad range of inflammatory markers, many of which had
not been previously assessed in AN. IL-15, VEGF-A, and TNF-β, for the first time, were shown to be
altered in people with AN in comparison to HCs. Previous findings regarding an elevation of IL-6 and
VCAM-1 and a reduction in BDNF in AN participants were replicated. We also considered age, BMI,
and percentage fat mass as potential confounding variables of concentrations of the inflammatory
markers. Our findings suggest that future research should include covariates in analyses of this
relationship to explore whether this may account for some of the group differences in inflammatory
markers observed in the current study. Finally, given that these inflammatory markers function as part
of a complex network, future studies in larger samples should consider developing a composite score
of cytokine concentrations.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/11/1573/
s1: Table S1: Findings from the linear regressions of potential confounders—age, BMI, percentage fat mass
(independent variable)—on log-transformed values of inflammatory markers (dependent variable) in the whole
sample; Table S2: Findings from the linear regressions of illness severity (independent variable) on log-transformed
values of inflammatory markers (dependent variable) in AN patients only.
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